Quality of T-cells after stimulation with leukemia-derived dendritic cells (DC) from patients with acute myeloid leukemia (AML) or myeloid dysplastic syndrome (MDS) is predictive for their leukemia cytotoxic potential.

Myeloid leukemic cells can differentiate into leukemia-derived dendritic cells (DC(leu)), presenting known/unknown leukemic-antigens. Induced anti-leukemic T-cell-responses are variable. To further elicit DC/DC(leu)-induced T-cell-response-patterns we performed (functional)flow-cytometry/fluorolysis-assays before/after mixed lymphocyte cultures (MLC) of matched (allogeneic) donor-T-cells (n=6), T-cells prepared at relapse after stem cell transplantation (n=4) or (autologous) patients'-T-cells (n=7) with blast-containing-mononuclear-cells ('MNC') or DC(leu)-containing DC ('DC'). Compared to 'MNC' 'DC' were better mediators of anti-leukaemic T-cell-activity, although not in every case effective. We could define cut-off proportions of mature DC, DC(leu), proliferating, CD4(+), CD8(+) and non-naive T-cells after 'MNC'- or 'DC'-stimulation, that were predictive for an anti-leukemic-activity of stimulated T-cells as well as a response to immunotherapy. Interestingly especially ratios >1 of CD4:CD8 or CD45RO:CD45RA T-cells were predictive for anti-leukemic function after DC-stimulation. In summary the composition and quality of DC and T-cells after a MLC-stimulating-phase is predictive for a successful ex-vivo and in-vivo anti-leukemic response, especially with respect to proportions of proliferating, CD4(+) and CD45RO(+) T-cells. Successful cytotoxicity and the development of a T-cell-memory after 'DC'-stimulation could be predictive for the clinical course of the disease and may pave the way to develop adoptive immunotherapy, especially for patients at relapse after SCT.

Liepert A ，Grabrucker C ，Kremser A ，Dreyssig J ，Ansprenger C ，Freudenreich M ，Kroell T ，Reibke R ，Tischer J ，Schweiger C ，Schmid C ，Kolb HJ ，Schmetzer H ... -  《-》

The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells.

Grabrucker C ，Liepert A ，Dreyig J ，Kremser A ，Kroell T ，Freudenreich M ，Schmid C ，Schweiger C ，Tischer J ，Kolb HJ ，Schmetzer H ... -  《-》

Dendritic cells (DCs) can be successfully generated from leukemic blasts in individual patients with AML or MDS: an evaluation of different methods.

Kremser A ，Dressig J ，Grabrucker C ，Liepert A ，Kroell T ，Scholl N ，Schmid C ，Tischer J ，Kufner S ，Salih H ，Kolb HJ ，Schmetzer H ... -  《-》

Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations.

Schick J ，Vogt V ，Zerwes M ，Kroell T ，Kraemer D ，Köhne CH ，Hausmann A ，Buhmann R ，Tischer J ，Schmetzer H ... -  《-》

Leukaemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with myelodysplasia: a methodological approach under serum-free culture conditions.

Kufner S ，Zitzelsberger H ，Kroell T ，Pelka-Fleischer R ，Salem A ，de Valle F ，Schmid C ，Schweiger C ，Kolb HJ ，Schmetzer HM ... -  《SCANDINAVIAN JOURNAL OF IMMUNOLOGY》